Biobizkaia
Forschungszentrum
University of Louisville
Louisville, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of Louisville (17)
2023
-
Impact of SARS-CoV-2 Infection on the Association Between Laboratory Tests and Severe Outcomes Among Hospitalized Children
Open Forum Infectious Diseases, Vol. 10, Núm. 10
2022
-
Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia
Medicina Intensiva
-
Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia
Medicina intensiva, Vol. 46, Núm. 8, pp. 426-435
-
Outcomes of SARS-CoV-2–Positive Youths Tested in Emergency Departments The Global PERN–COVID-19 Study
JAMA Network Open, Vol. 5, Núm. 1, pp. E2142322
2021
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
-
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score
British Journal of Surgery, Vol. 19, Núm. 4
-
Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: An international cohort study
BMJ Open, Vol. 11, Núm. 11
-
The State of Pulmonary Rehabilitation in Latin America During the COVID-19 Pandemic
Journal of the International Society of Physical and Rehabilitation Medicine, Vol. 4, Núm. 1, pp. 40-50
2019
-
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations
Parkinsonism and Related Disorders, Vol. 60, pp. 138-145
2018
2017
2016
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy
Movement Disorders, Vol. 31, Núm. 5, pp. 742-747
2015
-
Anti-C1q antibodies in systemic lupus erythematosus
Lupus, Vol. 24, Núm. 1, pp. 42-49
2014
-
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy
Movement Disorders, Vol. 29, Núm. 4, pp. 470-478
2012
-
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus
Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2677-2686